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Meta-analysis of Two-Treatment Clinical Trials Including
Both Continuous and Dichotomous Results
CHARLES F. BABBS, MD, PhD
Purdue University, West Lafayette, Indiana, USA 47907
(Medical Decision Making 24, 299-312, 2004)

ABSTRACT
To expedite the timely creation of medical practice guidelines, a meta-analytic method was
developed to combine of both dichotomous survival data and continuous physiologic data from
multiple studies comparing the same innovative clinical intervention to standard care. The
method is adapted for synthesis of small, early studies of novel treatments. An aggregate ratio,
R*, of the observed treatment effect to a clinically optimal treatment effect for studies in a series
is computed, and compared to the 95% confidence limit for R* under the null hypothesis.
Weights assigned to each study may reflect its precision, quality, or clinical relevance. Input
data for continuous variables include sample means, standard errors, and sample sizes. Input
data for dichotomous variables include group proportions and sizes. The analysis can be done
using a simple, one-page spreadsheet. It allows one to judge biological significance, to test for
statistical significance, to compare subgroups of studies for differences (heterogeneity of effect),
to test for outliers, and to compute the power of the meta-analysis. These features are
demonstrated for studies of interposed abdominal compression—cardiopulmonary resuscitation
(IAC-CPR). This novel method of meta-analysis can provide rapid, quantitative, and accurate
estimates of the amount of benefit or harm from an experimental clinical intervention, as
reported in multiple small independent studies of differing experimental design.
Key words (not in title): abdominal, cardiopulmonary resuscitation, confidence intervals,
continuous, data interpretation, evidence-based medicine, interposed abdominal compression
(IAC)-CPR, orphan drugs, pediatric research

Abbreviations: CPR, cardiopulmonary resuscitation, IAC, interposed abdominal compression,
ROSC, return of spontaneous circulation

INTRODUCTION
The fruits of research are sometimes like apples and oranges, i.e. they are not directly
comparable. This paper presents a general approach to the systematic analysis of two-treatment
experiments including a wide variety of study designs and end-points. Such heterogeneity is
typical of early research on an emerging therapy or concept, before experimental methods
become standardized. The approach was designed specifically as an aid to the evaluation of
evidence during development of guidelines for CPR and advanced cardiac life support. In this
field multiple large clinical trials of new interventions are rare or nonexistent—owing to the lack
of funding, the difficulty in obtaining informed consent from persons in cardiac arrest, the low
probability of survival from sudden cardiac death, the perception that the existence of standards
obviates the need for research, and the chaotic nature of the clinical setting during
cardiopulmonary resuscitation. Studies of innovative techniques in CPR include small numbers
of patients. Some focus on survival; others focus on physiologic end-points such as blood
pressure. Similarly, research synthesis relating to rare or orphan diseases, including many
pediatric conditions, often involves a paucity of heterogenous data. In these cases there is an
insufficient number of large controlled clinical trials to justify a formal Cochrane review1. Yet
patients must be treated anyway, and hence there will always be a need for clinical guidelines
based upon the best evidence available* .
An important early question in analysis of a new treatment or intervention in such data poor
areas of research is "does the new method work any better than the standard approach?" An
important related question is "does the new method work better in some subgroups of patients
than in others?" Quantitative statistical methods such as meta-analysis can help answer these
questions4. The novel meta-analytic method presented herein is applicable to any studies that
compare a new clinical intervention (drug, dose, or device) with a standard or control
intervention in diverse animal or clinical models. Outcome measures may differ greatly. Some
may be continuous data (e.g. physiologic measures like end-tidal CO2 concentration or mean
coronary perfusion pressure). Others may be dichotomous data (e.g. integer head counts of
patients resuscitated, discharged, etc.). It is only necessary that all of the studies relate to a
common focused question or test the same hypothesis and that the results of the different
measures are generally consistent. (If the patients die with "good numbers" for continuous
physiologic data, then, obviously, the survival data and the "numbers" are inconsistent, and
caution is necessary in combining them.)

*

The author has been personally involved in guideline creation in orphan research areas as Chair of the Research
Working Group, Emergency Cardiovascular Care (ECC) Programs, American Heart Association for the years 2000
to 2002. This committee was charged with developing methods of evidence evaluation used in creation of
international guidelines for cardiopulmonary resuscitation and emergency cardiovascular care2 The present work
was inspired by the challenges faced by the ECC committees, which had to make the most efficient possible use of
available data. The ECC committees began with traditional vote counting procedures, in which each positive
significant study “casts a vote” for, and each non-significant study “casts a vote” against, a proposed innovation.
This approach is, of course, strongly biased toward the conclusion that the experimental treatment has no effect.
Hence vote counting methods are no longer recommended for the task of research synthesis 3-5. The present paper is
an outgrowth of the author's search for a better alternative.
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Existing statistical methods are not satisfactory for this task. A simple sign test of the numbers
of studies having any observed positive effect of treatment, versus those with any observed
negative effect of treatment can be done. However, this approach ignores information about the
magnitudes of treatment effects. Conventional statistical tests using pooled data such as a t-test
or analysis of variance assume homogeneity of variance, which is unlikely to be true in multiple
small trials. Accordingly, such tests are usually deemed inappropriate for the purpose of
combining results in a meta-analysis5. Conventional meta-analysis using effect size for
continuous variables5 will not work, without modification, for dichotomous data such as the
proportion of survivors. Conventional meta-analysis using odds ratios6, 7 will not work for
physiologic data like blood pressure or blood flow. None of these methods deals formally with
the issue of biological significance.
The method meta-analysis, described herein, is an extension of the response ratio method
developed by Hedges and coworkers for synthesis of continuous data from studies in the field of
ecology8. It permits assessment of the statistical and biological significance of the combined
results from multiple small studies, which may include a mixture of continuous and dichotomous
end-points. It is straightforward and easily implemented on ordinary personal computers using
standard spreadsheet software.
METHODS
Terminology.
Definitions of symbols used to describe input data for the analysis are given in Table 1. The
symbols E and C refer to sample means of continuous data, such as end-tidal CO2 , from
experimental and control groups, respectively. The symbols p E and p C refer to proportions
obtained from experimental and control groups, such as the proportions of surviving patients.
True population variances for a random variable, X, are indicated by the symbol  2 ( X ) .
Estimates of population variances, obtained from measured data, are indicated by the addition of
a “hat” symbol, ˆ 2 ( X ) . Standard errors of the mean are indicated by a combined symbol, for
example ̂(E) . For continuous data ̂(E) and ̂(C) are taken as the published values for the
standard errors of the mean reported by the investigators for treatment and control groups. If
these values are not provided, they can be calculated using formulas in Table 2. For
dichotomous data ˆ (p E ) and ˆ ( p C ) may be computed from the expression for the variance of
the binomial distribution, ˆ 2 (p)  p (1  p) /(n  1) . Division by n-1 rather than by n provides
an unbiased estimate for the variance9 . For simplicity of notation, "hats" are not used for sample
means or proportions, which are understood to differ from the corresponding population values.
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Table 1. Nomenclature
Symbol

Definition for continuous data

E

Sample mean for treatment group

C
pE

Sample mean for control group
Proportion of individuals with favorable
outcome in the treatment group
Proportion of individuals with favorable
outcome in the control group

pC

I

Ideal result for a clinical study, the
best possible outcome

nE

Number of subjects in experimental
group
Number of subjects in control group

nC

Definition for dichotomous data

Ideal result for a clinical study, the best
possible outcome, typically 1.0 or 100 %
survival
Number of subjects in experimental group
Number of subjects in control group

̂(E)
or
ˆ (p E )

Published standard error of the mean
for the experimental group
(experimental group standard
deviation divided by n E )

p E (1  p E ) /(n E  1) , estimate of the
standard deviation of observed proportions in
multiple replications of the same study

̂(C)
or
ˆ ( p C )
R

Published standard error of the mean
for the control group (control group
standard deviation divided by n C )

pC (1  pC ) /(n C  1) , estimate of the
standard deviation of observed proportions in
multiple replications of the same study
p  pC
I  pE
R E
 1
 1  R'
I  pC
I  pC



EC
IE
 1
 1  R'
IC
IC
IE

  ln(R ' )  ln
IC
R

 I  pE 

  ln(R ' )  ln
 I  pC 
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Summarizing Research Findings as Clinical Result Ratios.
Clinical result ratios for two-group experiments are computed as shown in Table 2. They are
obtained by dividing the measured difference in outcome between experimental and control
groups by the clinically optimal difference in outcome for any particular end point. The
clinically optimal or ideal outcome, denoted I , would usually represent return to normal
physiologic status (for example, normal cardiac output or normal arterial blood oxygen content)
or 100 percent survival in the case of proportions. Hence, the clinical result ratio is either



R= EC

 I  C

(1a)

in a study with continuous physiologic end points or
R = p E  p C  I  p C 

(1b)

in a study of discrete endpoints such as survival. The result ratio, R, for each individual study
can be interpreted as a fraction of the best possible treatment effect that could have been found.
By convention outcomes are described as positive, such that a larger value indicates benefit. In
turn, a ratio R > 0 indicates greater benefit in the experimental group than in the control group.*
R = 1 indicates ideal benefit. R = 0 indicates no benefit. R < 0 indicates a worse result than
control. Zero values for E , C , p E , or p C are allowed. Note that the ideal outcome, I, in
expression (1a) is almost surely greater than the control group outcome, C ; otherwise the study
would not have been done. In expression (1b) the value of I is typically 1.0 or 100 percent
survival, which usually indicates the maximum possible clinical benefit. However, it is not
strictly true that the ideal survival is always 100 percent. For example, in long-term studies the
value of ideal outcome, I, could be taken as the predicted survival of healthy persons over the
same time period. (Although a common convention in statistics is to use upper case letters to
denote random variables and lower case letters to denote constants, in the present context I is a
constant.) Using the ideal result, I, as a point of reference allows one to combine clinical
response ratios for measures that have quite different scales and dynamic ranges. Since the
relative effect of treatment across studies is more constant than the absolute effect 11-13, use of
such response ratios is an advantage in meta-analysis.

*

In epidemiology10, outcomes are often reported as negative, e.g. mortality. Such results are easily translated into
survival. It is an interesting mathematical diversion to show that if I=100 percent for survival and I'=0 percent for
mortality, then R values computed directly from mortality data are the same as those computed from survival data.
Although experts may disagree somewhat on the definition of "ideal", small changes in the choice of the parameter,
I, do not influence the results of significance testing, as detailed in the Discussion section.
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Table 2. Computation of result ratios for continuous and dichotomous variables for an
individual study
Definition for continuous data
Clinical
Response
Ratio

R

Log
complement
of response
ratio

I  E
  ln(R )  ln 

I  C 

Variance of
the log
complement
of response
ratio*

ˆ 2 ()  2

Definition for dichotomous data

EC
IE
 1
 1  R'
IC
IC

R

p E  pC
I  pE
 1
 1  R'
I  pC
I  pC

 I  pE 
  ln(R )  ln 

 I  pC 

 

(n E  1) ˆ 2 E   (n C  1) ˆ 2 C

N  2I  P 

2

ˆ 2 () 

p (1  p )

(n C  1)I  p 

2



p (1  p )

(n E  1)I  p 

*For continuous data the estimates of the experimental and control group variances, namely

ˆ 2 ( E ) 

1
nE
E i  E 2 and ˆ 2 (C)  1 inc1 Ci  C 2

i 1
n E  1
n C  1

are usually provided in the reports of studies to be synthesized. If not they must be calculated
from the original data.

One practical issue in the computation of response ratios deserves mention here. For the purpose
of meta-analysis it is useful to use a single composite figure of merit to describe the treatment
effect in each particular study in a series. However, in many studies several different outcome
measures are reported (primary and secondary end-points), which may have somewhat different
ratios of experimental to control results. There are two approaches to this situation 14. The first
approach is to select a “best” end-point from each study that is most relevant to the question in
hand. This may well be the primary end point identified by the original investigators. To avoid
throwing away information in a data poor research area, however, it may be helpful to derive a
composite measure of treatment effect for each such study. Hence a second approach is to
compute an average composite R-value to represent the overall result of each study. (The
general solution to this problem is to use a weighted average of outcome measures within each
independent study, based on a predetermined framework defining the importance of the different
measures reported. The first approach, just described, is the special case in which the "best"
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outcome measure is given weight 1.00 and the all other measures are given weight zero. The
second approach requires treating the various within-study outcomes as correlated measures, for
which the standard deviation of the average is the average standard deviation.)
The result of this first phase of data abstraction is to create a single composite outcome measure,
R, for each independent study. These individual indices of effect can then be combined into an
aggregate index for the entire series of studies.
The Aggregate Response Ratio and its Distribution Under H 0 .
The objective of this section is to develop a test statistic from the combined response ratios from
multiple studies that has a known sampling distribution under the null hypothesis, H 0 . Then
significance testing for a meta-analysis will be possible. First we shall find well behaved test
statistics describing each individual study, and then we shall consider a weighted average of
these statistics across all studies in the meta-analysis.
Statistics for individual studies
Suppose one has assembled a series of m independent studies of a particular treatment and has
computed the clinical result ratio, R, for each study. To obtain a test statistic with a known
distribution under H0 , it is helpful to express result the ratio R for any particular study in terms
of its complement, R' = 1 - R, that is,

R

E  C I  C  I  E 
IE

 1
 1  R
IC
IC
IC

(1c)

or

R  1

I  pE
 1  R
I  pC

(1d)

and then to determine the distribution of R' values under the null hypothesis. Because the
distribution of ratios of random variables is skewed, it is standard practice to work with the
logarithms of ratios, which have a more symmetrical distribution that is better approximated by a
normal distribution15, 16. (Of course, to work with logarithms we must have R' > 0.) Under the
null hypothesis, when the expected values of the numerator and denominator of R' are equal, and
the coefficients of variation of the numerator and denominator of R' are also equal, then the
natural log of R' is very well approximated by a normal distribution having zero mean and
having variance given in Appendix 1 (A1.1). As shown in Appendix 1, the variance of log R'
can be determined directly, whereas the variance of R cannot, because the numerator contains the
difference of two random variables. The distribution of log R' is also very close to normal under
H0 (Appendix 1(b)). Moreover, the Central Limit Theorem provides a further argument for
approximate normality of the average logarithm of R' across studies, which will be used for
significance testing in the meta-analysis.
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Let the natural logarithm of R' = 1 - R be denoted by the Greek letter,  . Thus,

IE
 for continuous data, or
  ln(R ' )  ln
IC

(2a)

 I  pE 

  ln(R ' )  ln
 I  pC 

(2b)

for dichotomous data in any particular study. Under the null hypothesis, H0 , the mean value of
ˆ () , as
the distribution of  = ln(R') is zero ( ln(1) = 0 ), and the estimated standard deviation is 
defined in Table 2 and derived in Appendix 2. Because the distribution of  is symmetrical and
approximately Gaussian, one can readily compute the distribution of R  1  R'  1  e  and its
95 percent confidence limits.
An aggregate test statistic for meta-analysis
Now to conduct a meta-analysis of studies related to a common experimental intervention, one
may define a pooled test statistic for a series of m independent studies as

R*  1  e  ,

(3)

where  is a weighted average value of =ln(R') for the series, namely,



1 m
 w j j
W j1

(4)

with individual study weights wj, and W equal to the sum of the weights. The virtue of using
R* for meta-analysis is that confidence limits can be obtained for this statistic under H 0, based
upon the known, approximately normal distributions of the random variables j.
The weights can be assigned with due caution and good judgment 17, 18 to reflect the relevance or
the quality of the studies. Generally, precise guidelines should be drawn up in advance. One
option is to set all weights equal to 1, in which case W = m . In this case all studies that are
deemed relevant to the question at hand are given weight 1 , and all studies that are deemed
irrelevant are given weight zero. Another popular option is the use of inverse variance
weighting, which gives greater weight to experiments whose estimates have greater statistical
precision. Inverse variance weights produce minimum variance of the overall weighted
average19, 20.
A formal process of assigning weights makes the relative contribution of each study explicit. In
addition, the explicit weights in expression (4) make it technically easy to repeat a meta -analysis
with each study in turn omitted. One simply sets the weight of each study temporarily to zero
and observes the effect upon the results. Such an exercise helps to determine if any one study

8

drives the final conclusions of the meta-analysis. The use of weights also expedites the
comparison of subgroups of studies, as subsequently explained.
To test R* for statistical significance and to make cumulative meta-analysis plots we wish to find
95 percent confidence limits associated with R* when the null hypothesis is true. This task is
easily done as follows. The estimated variance of  is

S2  ˆ 2   





1
w 12 ˆ 2 (1 )  w 22 ˆ 2 ( 2 )    w 2m ˆ 2 ( m ) .
W2

(5)

Expression (5) derives from the general principle that the variance of the sum of independent
random variables is equal to the sum of the variances. Here the component -values are
obviously independent, since they come from different studies, each of which must include
different subjects. The variance estimates for the -values from each study are computed from
measured data as shown in Table 2, the expressions for which are derived in Appendix 2.
If we assume that under the null hypothesis  has a normal distribution with mean value zero

and standard deviation S, as is reasonable**, then
has a standard normal distribution. In turn,
S
the 95 percent confidence interval under the null hypothesis for  is 0  1.96S . Hence, the
lower and upper critical values for significance testing of R* with  = 0.05 are



C L  1  e 1.96 S







to C U  1  e 1.96 S .

(6)

By calculating the empirical R* value and comparing it to the critical values 1  e 1.96 S  , one
obtains a rapid test of significance for biologically meaningful effects of treatment in the entire
series of m studies. (Note that the confidence interval for the mean log R' value is symmetrical,
but the back-transformed confidence interval for R* is not.)
Alternatively, one may calculate the classical p-value for the two-sided test H0:  = 0 vs. H1  
0 as p  2


 /S

f ( x ) dx , two-tailed, where f(x) is the probability density function for the normal

distribution.

**

A virtue of the log transformation is that the log result ratios are approximately normally distributed.
Further, by virtue of the central limit theorem21, an average of several log result ratios is even better
approximated by a normal distribution. Because S  ˆ (  ) is actually an estimate derived from sample
data, and hence a random variable, the distribution of  / S will resemble a t-distribution. However, one
can show, along the lines of Welch22, that  / S is distributed very much like a t-distribution with a
number of degrees of freedom roughly equal to the number of patients in all studies synthesized. Thus for
a typical meta-analysis assumption of a normal distribution is very reasonable.
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Power of the Meta-analysis.
Under H0 the mean value of the distribution of  is zero ( ln(1) = 0 ), and the standard deviation
is S, computed from expression (5). Because the distribution of  is normal, one can also
calculate the power of the meta-analysis for an alternative hypothesis, H 1 , that the true effect is at
least, say, 10 percent of the ideal benefit, and assuming that S is the same under these
circumstances, which is very nearly true. (Under H 1 there is a slight skewness to the distribution
of  , which can be ignored in power calculations.) Then, for R = 0.1 the mean value of  is
given by R  0.1  1  e  or    ln(0.9)  0.105 . (Note   is negative for a positive
treatment effect.) In this case the beta error, or probability of a false negative evaluation of the
experimental treatment, is



  / S  1.96 



f ( x )dx ,

(7)

where f(x) is the probability density function for the normal distribution, and    0 . The power
of the meta-analysis is 1 - . The usefulness of computing the statistical power of a metaanalysis has been emphasized recently by Hedges and Pigott23 .
Cumulative Meta-analysis.
Using the graphical approach similar to Lau and coworkers7, 24 one can construct a cumulative
meta-analysis plot showing successive values of R*  1  e  in relation to the critical values for
rejection of the null hypothesis after publication of each study in the series being analyzed. Such
a plot shows how the significance of the overall treatment effect evolves with the publication of
new data.
Omitting Individual Studies.
Critics will often object to one study or another on technical grounds, raising the question as to
whether the entire analysis is flawed because an offending study has been included. To explore
the influence of individual studies on the conclusions of the analysis one can make a table of the
aggregate R* statistics and their confidence limits, first when no study, and then when each
study in turn is omitted from the analysis by setting its weight, w, equal to zero. If the results do
not differ substantially (the usual outcome) then one can conclude that no single study drives the
conclusions of the analysis.
Comparing Subgroups of Studies for Heterogeneous Effects.
Suppose one finds among the studies in a meta-analysis two apparent subgroups of studies that
differ in treatment effect, possibly on the basis of differences in patient populations, treatment
implementation, or hospital setting. To test whether there is there a significant difference in the
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treatment effect between the subgroups one can re-do the meta-analysis twice—first setting the
weights for subgroup 2 to zero, leaving subgroup 1, and then setting the weights for subgroup 1
to zero, leaving subgroup 2. The difference in mean log(R'), namely d  1   2 , between
subgroup 1 and subgroup 2 can be tested for statistical significance. Since, the subgroups are
independent, the variance of the difference is the sum of the variances,
S12  S 22  ˆ 2 ( 1 )  ˆ 2 (  2 ) , which are automatically available from the separate meta-analyses
of the subgroups. The expected standard deviation of subgroup differences is Sd  S12  S 22 . In
turn, the 95 % confidence interval for d is 0  1.96 S d under the null hypothesis that d = 0. If the
observed d lies within this confidence interval, there is no significant difference between the
subgroups. Such a “d-test” can avoid needless speculation over differences explained merely by
sampling variation.
Test for Outliers.
If the difference, d, between a subgroup of m=1 study and the remaining m-1 studies is clearly
significant, for example, if the absolute value of d is greater than, say, 3 times S d , then the
study may be unidentified as an outlier.
Spreadsheets for Performing Meta-analysis.
A standard spreadsheet program such as Microsoft Excel is sufficient to perform a meta-analysis
of clinical response ratios. No macros or programming are needed. Costly special purpose
software is not required. There are two general phases of calculation. The first is obtaining the
R- and -statistics for each study. The second is running the meta-analysis itself. These phases
can be performed in different sections of the spreadsheet, as shown in Tables 3 and 4. These
tables were copied directly form a working spreadsheet, a template for which can be obtained
from the author at no cost** and modified for similar meta-analyses of various topics.

SAMPLE RESULTS FOR IAC-CPR
Sources.
During interposed abdominal compression (IAC)-CPR manual pressure is applied to the
abdomen of the victim 180 degrees out of phase with the rhythm of chest compression, so that
the abdomen is being compressed when chest pressure is relaxed, and vise versa. This technique
has been studied in a variety of mathematical, mechanical, animal, and clinical models with
generally positive results25 . For simplicity only human studies are included in the present metaanalysis. These relatively small, initial studies gathered a mixture of continuous physiologic data
and dichotomous survival data, which are well suited for analysis in terms of clinical response
ratios. Full length, peer reviewed publications were identified using evidence evaluation
**

E-mail: babbs@purdue.edu
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worksheets created by the research working group of the American Heart Association 26.
Individual trials were obtained from MEDLINE searches, the author’s files, and reference lists of
review articles on newer techniques in resuscitation as referenced in 2. All studies compared
patients receiving IAC-CPR with those receiving standard CPR. The end points analyzed
include blood pressure, end tidal CO2, frequency of return of spontaneous circulation, and
frequency of hospital discharge with intact neurological function. Altogether there are 7 separate
results reported in the 5 studies. Criteria for quality and relevance of the studies are defined in
terms of "Levels of Evidence", developed by the American Heart Association and described in
detail previously26 . The four Level 1 studies are weighted 1, and the one Level 2 study is
weighted 1/2. The reduced weight for the Level 2 study is a conservative choice, since this
initial non-randomized trial had strongly positive results.
Composite  values for individual studies.
Results of data reduction for the 5 available clinical studies of IAC-CPR are shown in Table 3.
Successive studies are arranged by columns from left to right. The column for the fourth study
(Sack, 1992) is subdivided to accommodate multiple dichotomous end points. Data from each
study are entered in two blocks—the upper block for continuous data and the lower block for
dichotomous data. In Table 3 continuous data include mean arterial pressure and end-tidal CO2,
which is reflective of forward blood flow. Control and experimental means and their respective
standard errors appear in successive rows. Next the experimental/control result ratio, R, and the
more normally distributed logarithm of 1-R, denoted , are computed, together with the variance
estimate for  using the formula shown in Table 2 and Appendix 2 (A2.5a).
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Table 3. Raw and composite outcome data from independent human studies of IAC-CPR*
Study ID
Date

Berryman
1984

Mateer
1985

Ward
1989

Sack 1**
1992

Sack 2
1992

Continuous Data
End point
Con mean
Con SEM
Exp mean
Exp SEM
Con N
Exp N
R
R'
Grand Mean
= ln(R')
V()

MAP
26
1
39
1.6
6
6
0.1884
0.812
32.5
-0.209
0.000911

ET-CO2
9.6
1
17.1
1.5
33
33
0.3676
0.632
13.35
-0.458
0.0117

Dichotomous Data
End point
Con survivors
Con N
Exp survivors
Exp N
Con p
Exp p
R'
R
Grand p

V()

ROSC
45
146
40
145
0.3082
0.2758
1.04677
-0.04677
0.292096

ROSC
3
17
6
16
0.1765
0.375
0.7589
0.2411
0.2727

0.045713
0.005711

-0.2758
0.0484

0.0457
0.00571

-0.3671
0.0301

ROSC Discharge ROSC
14
3
21
55
55
76
29
8
33
48
48
67
0.2545
0.0545 0.2763
0.6041
0.1666 0.4925
0.531
0.88141 0.70122
0.469
0.11859 0.29878
0.41748
0.1068 0.37762
-0.633
-0.1262 0.35493
0.02852
0.00476 0.01728

Composite Data
Mean 
Mean V()

-0.2087
0.00091

xxx
xxx

-0.3796 -0.3549
0.01664 0.01728

*Abbreviations: Con = control, Exp = experimental, ET-CO2 = end tidal carbon dioxide
concentration, hits = number of patients with favorable outcome, ID = identifier, MAP = mean
arterial pressure, N = number of patients in a group, ROSC = return of spontaneous circulation,
SEM = standard error of the mean
** Two columns accommodate two dichotomous variables, ROSC and discharge survival.
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The lower block in Table 3 is for dichotomous survival data, including return of spontaneous
circulation (ROSC) and discharge survival. The nature of dichotomous data requires different
summary statistics. Numbers of good outcomes (“survivors”) in both control and experimental
groups and the respective group n’s are tabulated, together with associated proportions. The
variance estimate for the log result ratio with dichotomous data is computed from observed
proportions as shown in Table 2 and Appendix 2 (A2.5b).
A key feature of the meta-analysis is generation of a single figure of merit, describing the result
of each independent study. In Table 3 the mean log result ratio for all end points within a study
is used to create such an estimate of treatment effect. Similarly, the mean variance estimate for
all end points within a particular study is used to create an estimate of the typical variance of the
result ratio for that study. This variance estimate is suitable for highly correlated variables
within a particular study.
Cumulative Meta-analysis.
Results of cumulative meta-analysis for IAC-CPR are shown in Table 4 and in Figure 1. Table 4
is a continuation of the same spreadsheet shown in Table 3. The composite -values and their
variances at the bottom of Table 3 for each of the 5 independent studies, involving entirely
different patients, are transferred to the upper rows of Table 4 for each study. Here, working
from left to right, a weighted mean -value and its estimated standard deviation are found using
expressions (4) and (5). Successive columns from left to right represent successive stages of the
cumulative meta-analysis. The mean -value under Study 1 describes the first study only. The
mean -value under Study 2 describes the combined results of the first two studies. The mean value under Study 3 describes the combined results of the first three studies, etc. Subsequent
rows of R* data and associated critical values are obtained from the mean  data by exponential
transformation using expressions (3) and (6). Note that the power of the over-all analysis to
detect an R* of 0.1 or greater increases substantially after publication of the third study (Table 4,
bottom). Such calculations of beta error and statistical power can be useful to evaluate the
possibility of Type 2 error in the event that the aggregate R* value is not significant.
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Table 4. Cumulative meta-analysis of human studies of IAC-CPR

Study Weight
Study Number
Composite 
Composite V()
Weight*
Weight2*V()

̂ (  )
Ratio R*
Critical pt.
Critical pt.
p-value
Beta
Power

Study 1
0.5
1
-0.2088
0.0009
-0.1044
0.0002
-0.2088
0.0302
0.1884
-0.061
0.0575
5E-12
4E-07
1

Study 2
1
2
0.0457
0.0057
0.0457
0.0057
-0.0391
0.0514
0.0384
-0.10594
0.09579
0.44651
0.88469
0.11531

Study 3
1
3
-0.3671
0.0301
-0.3671
0.0301
-0.1703
0.0759
0.1566
-0.1604
0.13825
0.02488
0.38849
0.61151

Study 4
1
4
-0.3796
0.0166
-0.3796
0.0166
-0.2301
0.0656
0.2055
-0.13713
0.12059
0.00045
0.06062
0.93938

Study 5
1
5
-0.3549
0.0173
-0.3549
0.0173
-0.2578
0.0588
0.2273
-0.1221
0.1088
0.00001
0.00761
0.99239

Figure 1 is a plot of the aggregate result ratio, R*, and the associated critical values with
publication of successive studies. The left-most data point represents the historically first trial,
the second a combination of the first two trials, the third a combination of the first three, etc.
The separate lighter weight lines, without data points, are upper and lower critical values; they
include the 95 percent confidence intervals for R* under the null hypothesis. The data points and
critical values plotted in Figure 1 correspond to the summary data in the columns of Table 4
from left to right. A significant aggregate effect of treatment in humans is achieved and
maintained after the publication of the third study. The effect of IAC-CPR is both biologically
and statistically significant. Biological significance can be judged from the absolute value of R*,
here 20 percent of the ideal value of 1.0. Statistical significance can be judged from the
difference between R* and the nearest critical value.
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0.5
R*
C upper
C lower

Aggregate Response Ratio, R*

0.4

IAC-CPR

0.3
0.2
0.1
0
0

1

2

3

4

5

6

-0.1
-0.2
Study Number

Figure 1. Cumulative meta-analysis of human studies of interposed abdominal
compression CPR. In this horizontal format solid data points represent successive
aggregate R* values computed from the data. The separate upper and lower curves
represent critical values for statistical significance. Under the null hypothesis data points
can be expected to occur between the upper and lower curves 95 percent of the time.

Analysis with Studies Omitted.
Table 5 shows results of meta-analysis of IAC-CPR when each of the 5 studies in turn is given
zero weight. No single study drives the conclusion that IAC-CPR produces statistically
significant benefit compared to standard CPR.
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Table 5. Effects of omitting single studies

Ratio, R*
Upper critical value

None

1

0.227
0.109

0.232
0.121

Study omitted
2
3
0.291
0.132

0.203
0.106

4

5

0.200
0.121

0.206
0.121

Subgroup Analysis.
Retrospectively, however, there does appear to be a difference between the four in-hospital
studies and the one pre-hospital study of IAC-CPR. When the weights of all other studies are
set to zero, the R* value for the one out-of-hospital study (study number 2) is -0.05. When the
weight of study 2 is set to zero, the R* value for the remaining in-hospital studies is +0.29. A dtest, as described in Methods, for the difference in log(R') shows that the difference is greater
than 3 standard deviation from zero. The failure of the one pre-hospital study to demonstrate a
difference is explained by the substantial periods of standard CPR necessarily received by
patients in the IAC-CPR group both before arrival of emergency medical personnel and during
transport to the hospital2. Thus there is strong evidence, in particular, for the use of IAC-CPR in
a hospital setting.

DISCUSSION
To speed the translation of valid research findings into clinical practice, guideline writers must
make the most efficient use of available data, using methods such as cumulative meta-analysis7.
The present statistical approach is a form of cumulative meta-analysis applicable to both
continuous and dichotomous data, which tend to crop up heterogeneously in emerging research
areas and in studies involving less common disease entities. Because the patients in one study
are never compared directly with those in another study, it is not necessary to assume that the
trials synthesized are exactly comparable (a Petonian approach 27, 28)—only that they test the
same basic intervention as it might be implemented in various settings in the real world. Using
clinical response ratios, the particular studies to be included in a meta-analysis can be selected on
scientific and medical grounds, not on the basis of technical statistical requirements such as
homogeneity of variance or the need to treat continuous and dichotomous data differently.
There are a variety of other helpful aspects of working with clinical response ratios. Clinical
response ratios describe biologically meaningful effects of treatment, allowing synthesis of
various end-points on a scale from 0 to 1.0, representing no improvement to maximal desirable
improvement. R* = 0 indicates absolutely no evidence of clinical benefit versus control. R* = 1
indicates maximal or ideal clinical benefit. R* > C U indicates significantly better performance of
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the experimental treatment than the control. R* < C L indicates significantly poorer performance
than control.
Use of R* statistics rather than simple ratios of experimental to control end-points8 allows
synthesis of measures with a wide variation in dynamic ranges, for example arterial blood pH,
for which the biological range is about 7.1 to 7.6 versus arterial blood pO 2 , for which the
biological range (including 100 percent oxygen breathing) is about 40 to 400 torr. A strength of
the present method of meta-analysis is that the test of the null hypothesis itself does not depend
on the fixed effect assumption. There is no formal requirement that the components of  in
expression (4) have the same mean or that they have the same variance. It is simply an average
of independent random variables. However, these values are normalized to a biologically
meaningful range by introduction of the ideal response factor, I.
Importantly, the significance test for Type 1 error is not sensitive to small differences in expert
opinion regarding the choice of the normal values, I. This fact can be demonstrated numerically
in specific examples and also analytically by calculus***.
There may be some minor abuse potential in the choice of values, I , because there is some
latitude in deciding what the ideal therapeutic response would be. Typically changes of
continuous variables from abnormal to the mid normal value would be reasonable choices for
ideal therapeutic benefit. Changes in dichotomous variables to 100 percent survival or response
rates are similarly obvious choices. It would be difficult for biased analysts to circumvent these
obvious choices, which will be visible for readers to judge and dispute if they wish.
A minor technical advantage of the present method using the ideal response factor over the
simple response ratio method8 is that it can be used for experiments in which the mean control
value is zero or near zero. In such cases the denominator of the simple response ratio method
would be too small.
The general notion of combining various types of data in one analysis is based upon the idea that
the first step in the generation of clinical practice guidelines is simply to determine if a proposed
treatment, in general, produces favorable effects27 . If it does, then the effects that are seen in the
selected trials are likely to generalize to the even broader range of circumstances found in
widespread practice. When data are abundant possible heterogeneity of treatment effect among
***

The analytical result (given here without detailed proof) is that as the value of ideal outcome,
I, is changed by a modest amount, I, the relative change in the upper limit for significance
testing, cU is approximately proportional to the change in clinical response ratio, R. That is,
dc U R
. Accordingly, as I is changed, both the test statistic, R, and the critical value for

cU
R

significance testing, cU, increase or decrease by the same percentage. Hence the result of the
significance test is not influenced by small changes in I. In outline, the proof includes
differentiation of expression (1) with respect to I to obtain dR/R, use of the small value
approximation of ex in expression (6) and noting that

dc U dS
, then finding dS/S by

cU
S

differentiation of expression (5), and noting that the result is the same as dR/R.
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sub-populations becomes a major question. In the example of IAC-CPR, even with only five
clinical studies to analyze, there is evidence that the method may be more effective for inhospital resuscitation than for out-of-hospital resuscitation. In meta-analysis there seems to be a
tradeoff between combining heterogeneous studies, which increases generalizability, and
combining only homogeneous populations, which reduces variation but also reduces
generalizability. The use of an overall significance test, followed by subgroup analysis, allows
one to do the former, followed by the latter, obtaining the benefits of both.
The quality of any meta-analysis sis is heavily influenced by the quality of the studies included.
Selection of studies depends greatly upon the viewpoint of the meta-analyst and the framing of
the question to be addressed. Selection also may depend on subjective ratings of study quality,
which can vary greatly17. Language bias may exclude trials published in languages other than
English29. Data can be double counted inadvertently, for example in a separate single-center
report of some of the same patients that are included in a multi-center trial. Studies with nonsignificant results -- especially ones with small sample sizes -- may be less likely to be published
(publication bias), and hence may not be accounted in a formal meta-analysis29 . Such biases can
be minimized by a vigorous effort to include all relevant studies.
The explicit weighting factors in expressions (4) and (5) for the various studies may be viewed
negatively as easily abusable fudge factors that could be used to skew an analysis in one
direction or another, depending on the bias of the reviewer17, 18. In general, inclusion of all
studies is recommended, using either equal weighting for quality 5, 14, 30 or inverse variance
weighting19, 20. The seeming arbitrariness of weights may be unsettling to those unfamiliar with
meta-analysis. If concern arises one can perform a sensitivity analysis by re-running the metaanalysis with alternative weights and presenting the results in a table, similar to Table 5.
Typically the main results of the meta-analysis will be insensitive to changes in the weighting
scheme, giving the reader confidence that the weights were not chosen to produce a particular
result.
It is important to realize, however, that any synthesis of research findings will include the
unavoidable selection bias of the reviewer, who must choose which studies to include a nd which
to omit from the review (i.e. assigning weights equal to zero). If the explicit weights were
omitted from expressions (4) and (5), then all included studies would have weight 1 and all
excluded studies would have weight zero. The explicit weights merely highlight the necessary
judgments required, forcing the reviewer to disclose subjective decisions.
A weighting scheme of particular interest is the inverse variance weighting. As shown by
Hedges19 , selecting weights that are inversely proportional to the variances of individual random
variables minimizes the variance of their sum. Such weights give the narrowest 95 percent
confidence interval for the sum. Inverse variance weighting is easily implemented in
spreadsheets such as Table 4, because variances of study log R' values are already calculated as
shown in Tables 2 and 3.

19

CONCLUSIONS
When used properly and wisely, meta-analysis of clinical response ratios is a flexible tool to
expedite the timely and accurate syntheses of early research findings in clinical medicine. In
particular, meta-analysis may be used for combining studies in research areas where large
clinical trials would not be practical or would be unethical—for example in the field of
cardiopulmonary resuscitation where the issue of informed consent becomes quite difficult. The
present method provides quantitative tests of both Type 1 and Type 2 statistical errors, which
would lead respectively to either false positive or false negative evaluations of emerging
treatments, approaches, or concepts. Such information can guide individual and institutional
practice and shorten the time between research discoveries and their clinical implementation,
especially in neglected "orphan" areas.

Appendices
Appendix 1. Variance estimate for the logarithm of a ratio of random variables
(a) Application of the delta method
The probable error method or delta method16, 32 may be used to approximate variances of
functions of random variables. If X is a random variable with mean  and variance 2 , the
2
variance  2 (f (X))   2 (X)f () where f (X) is the first derivative of function f(X) with
respect to X. To appreciate the approximation one can visualize the function f(X) as a graph
with a tangent of slope f () at point (, f () ). By deduction from such a graph, it follows that
the standard deviation of f(X) is approximately f () times the standard deviation of X, as long
as f (X) does not change greatly over the range of X.
1
For the case of f (X)  ln(X) , the delta method gives  2 (ln(X))  2  2 (X) .

Hence,

  X 
ˆ 2 (X) ˆ 2 (Y)
ˆ 2 ln   ˆ 2 ln(X)  ln(Y)  ˆ 2 [ln( X)]  ˆ 2 [ln( Y)] 

.
X 2 Y 2
  Y 

(A1.1)

To explore limits of approximation (A1.1) and the shape of the distribution of ln(X/Y), a more
detailed treatment is as follows.
(b) Application of a series expansion
Let X and Y be two independent random variables, each always > 0. Let us represent X and Y as
X   x   x U1 and Y   y   y U 2 , where constants  x and  y are population means,  x
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and y are standard deviations such that / < 1, and random variables U1 and U2 are
distributed as N(0,1), that is U1 and U2 are independent standard normal deviates. Now
consider the ratio

X  x 1  c x U1 
,

Y  y 1  c y U 2 

(A1.2)

where cx and cy are coefficients of variation (/), which are typically < 0.3 in order to keep X
and Y > 0. Now


X
ln   ln x

Y
 y


  ln1  c x U 1   ln1  c y U 2  .



(A1.3)

1
1
l
Using two terms of the series expansion ln1        2   3   4   for   1 , which
2
3
4
can represent all but the largest occasional values of X and Y, we have

X
ln   ln x

Y
 y


  c x U 1  c y U 2  1 c 2x U 12  c 2y U 22   .

2






(A1.4)

From inspection of the series expansion, the random variable (A1.4) equals a constant,
ln  x /  y , plus a normal deviate with variance c 2x  c 2y (i.e. the combination of c x U1 and





c y U 2 ), plus a smaller correction term. The variance of the first three terms is given by (A1.1).
The correction term is the difference of two random variables that are distributed as U2, namely a
chi-square distribution with one degree of freedom. If c x = cy , then the distribution of the
correction term will be symmetrical about zero, and the correction will add a small amount of
extra noise or variance to the distribution of the normal approximation.
Given that standard normal deviates 1 and 2 are independent, that U2 is not correlated with U,
and that the variance of a chi-square distribution with 1 degree of freedom is 2, we have

  X 
 2  ln    c 2x  c 2y  c 2x
  Y 

   c  , or

  X 
  ln    c 2x  c 2y
  Y 
2





2

2 2
y

   

2

c 2x  c 2y
1 
c 2x  c 2y



2


.



(A1.5)

If cx = cy = c , then the ratio of the variance of the actual distribution to that of the approximation
of (A1.1) is 1 + c2 . For example if c = 1/4, then the variance ratio is
1
1 + 1/16. The ratio of the standard deviations is approximately 1 c 2 , or about a 3 percent
2
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difference. Indeed, expression (A1.5) could be used to further refine variance estimates in Table
2; although the correction would be small. Thus when c x = cy the normal approximation to the
distribution of ln(X/Y) is quite good.
In contrast, however, if cx >> cy , or if cx << cy , then the mean value of the chi-square correction
1
term  c 2x U12  c 2y U 22 will be nonzero, introducing skewness as well as noise to the actual
2
distribution of ln(X/Y). In the limiting case, in which c = c x >> cy or cx << cy = c the amount of
the shift in the mean will be 0.5 c2 E(U2) = 0.5 c2 , where the expected value of a chi-square
distribution with 1 degree of freedom, E(U2), is 1.0. For example, if c x = cy = 0.25 for typical
data, then the bias due to skewness would be 0.0625. In practical meta-analyses the observed
value of log response ratios ln(X/Y) may be in the neighborhood of 0.10 . Thus, the effect of
skewness can be a substantial fraction of the effect of experimental treatment when c x  c y . For
this reason variance estimates using (A1.1) and the assumption that ln(X/Y) is normally
distributed apply most accurately to cases where the coefficients of variation of X and Y are the
same, in particular H 0 :  x   y ,  x   y .





Appendix 2. Variance estimate for the complement of the log clinical result ratio, R', for
an individual study under the null hypothesis
For a particular study,

IE
 for continuous data, and
  ln(R ' )  ln
IC

(A2.1a)

 I  pE 
 for dichotomous data.
  ln(R ' )  ln
 I  pC 

(A2.1b)

We wish to estimate the variance of the 's under the null hypothesis that there is no true effect
of treatment on the sampling distributions for experimental and control data. One can estimate
the variance of the distribution of =ln(R') values, using the relationship

  X  ˆ 2 (X) ˆ 2 (Y)
ˆ 2 ln  

2
  Y  X 
Y 2

(A2.2)

derived in Appendix 1. Note that A2.2 assumes that X and Y are independent, which is true for
independent experimental and control groups in most clinical trials, because they contain
different patients. The required variance estimate for continuous variables is
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  I  E 
ˆ 2 E 
ˆ 2 C 
 
.
ˆ 2 ()  ˆ 2 ln

2
I  C 2
  I  C  I  E 
Under H0: E  C  P , the common population mean, and  2 E    2 C    2 P  , so

ˆ 2 ()  2

ˆ 2 P 

I  P 

2

.

The best estimate of the population mean under H 0 is the pooled common sample mean

P

nE E  nC C
N

(A2.3a)

for continuous data, or the pooled common proportion of successful outcomes

p

n E pE  n C pC
for dichotomous data,
N

(A2.3b)

where N  n C  n E is the total number of subjects in the study.
For continuous data a well-accepted estimate of the common population variance under H 0 is

ˆ 2 P  

(n E  1) ˆ 2 E   (n C  1) ˆ 2  C 
,
N2

(A2.4a)

which is a weighted average of the sample variance estimates, the weights being the respective
degrees of freedom.
For dichotomous data we assume that the true proportion of survivors under H 0 is given by
(A2.3b). For binomial distributions the variances of control and experimental proportions
depend upon the sample sizes nC and nE , which could be different31 ( p 234). In this case an
unbiased estimate of the variance for the control group under H 0 is

ˆ 2 p C  

p (1  p )
.
nC 1

(A2.4b)

Similarly, an unbiased estimate of the variance for the experimental group under H 0 is

ˆ 2 p E  

p (1  p )
.
nE 1

(A2.4c)
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Now using expressions (A2.3a) for P and (A2.4a) for ˆ 2 P  , we can compute the desired
variance estimate for  derived from continuous data under H 0 as

ˆ 2 ()  2

ˆ 2 P 

2

I  P 

2

(n E  1) ˆ 2 E   (n C  1) ˆ 2  C 

N  2 I  P 2

.

(A2.5a)

Similarly, we can compute the desired variance estimate for  derived from dichotomous data
under H0 as

  I  pE
ˆ 2 ln
  I  pC


ˆ 2 p C 
ˆ 2 p E 
 

, where under H0 p E  p C  p , and
2
2




I

p
I

p

E
C

substituting expressions (A2.4b) and (A2.4c), we have for dichotomous data

ˆ 2 () 

p (1  p) /(n C  1)

I  p 

2



p(1  p) /(n E  1)

I  p 2

.

(A2.5b)
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